TY - JOUR
T1 - Twice daily oral administration of Palmaria palmata protein hydrolysate reduces food intake in streptozotocin induced diabetic mice, improving glycaemic control and lipid profiles
AU - McLaughlin, Christopher M.
AU - Sharkey, Shaun J.
AU - Harnedy-Rothwell, Pádraigín
AU - Parthsarathy, Vadivel
AU - Allsopp, Philip J.
AU - McSorley, Emeir M.
AU - FitzGerald, Richard J.
AU - O'Harte, Finbarr P.M.
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020/10
Y1 - 2020/10
N2 - This study investigated the antihyperglycaemic effectiveness of an oral Palmaria palmata protein hydrolysate (PPPH), versus metformin, upon metabolic control in streptozotocin (STZ)-induced diabetic mice. Mice were administered PPPH (50 mg/kg bodyweight) or metformin (200 mg/kg bodyweight) by oral gavage twice-daily for 18 days. Blood glucose and plasma insulin were measured every third day. PPPH caused a significant reduction in blood glucose (p < 0.001) and a significant increase in plasma insulin (p < 0.001) versus STZ-treated saline controls. PPPH treatment reduced energy intake (p < 0.05), bodyweight (p < 0.01) and total plasma glucagon-like peptide-1 (p < 0.01) after 18 days. Terminal oral glucose tolerance (Day 18, p < 0.05), fasting blood glucose (p < 0.001), HbA1C (p < 0.01), plasma cholesterol (p < 0.01) and plasma triglycerides (p < 0.05) were significantly improved versus STZ-treated saline controls. All groups showed significant increases in pancreatic islet area, β-cell area, and β:α cell ratio. PPPH demonstrated potent antidiabetic potential in vivo through reduced food intake and improved beta-cell function.
AB - This study investigated the antihyperglycaemic effectiveness of an oral Palmaria palmata protein hydrolysate (PPPH), versus metformin, upon metabolic control in streptozotocin (STZ)-induced diabetic mice. Mice were administered PPPH (50 mg/kg bodyweight) or metformin (200 mg/kg bodyweight) by oral gavage twice-daily for 18 days. Blood glucose and plasma insulin were measured every third day. PPPH caused a significant reduction in blood glucose (p < 0.001) and a significant increase in plasma insulin (p < 0.001) versus STZ-treated saline controls. PPPH treatment reduced energy intake (p < 0.05), bodyweight (p < 0.01) and total plasma glucagon-like peptide-1 (p < 0.01) after 18 days. Terminal oral glucose tolerance (Day 18, p < 0.05), fasting blood glucose (p < 0.001), HbA1C (p < 0.01), plasma cholesterol (p < 0.01) and plasma triglycerides (p < 0.05) were significantly improved versus STZ-treated saline controls. All groups showed significant increases in pancreatic islet area, β-cell area, and β:α cell ratio. PPPH demonstrated potent antidiabetic potential in vivo through reduced food intake and improved beta-cell function.
KW - Blood glucose
KW - GLP-1
KW - Insulin secretion
KW - Palmaria palmata
KW - Protein hydrolysate
KW - Streptozotocin induced diabetes
UR - http://www.scopus.com/inward/record.url?scp=85087740224&partnerID=8YFLogxK
U2 - 10.1016/j.jff.2020.104101
DO - 10.1016/j.jff.2020.104101
M3 - Article
AN - SCOPUS:85087740224
SN - 1756-4646
VL - 73
JO - Journal of Functional Foods
JF - Journal of Functional Foods
M1 - 104101
ER -
